Adamis Pharma perks up on Mylan's EpiPen rhubarb; approval looming for its own epinephrine pre-filled syringe; shares ahead 17%

• Thinly traded nano cap Adamis Pharmaceuticals (ADMP +16.6%) heads north on a 22x surge in volume as investors take positions anticipating FDA approval of its Epinephrine Pre-filled Syringe (epinephrine injection USP 1:1000, 0.3 mg pre-filled single-dose syringe) for the emergency treatment of allergic reactions. The company filed its New Drug Application in May 2014.
• Market leader Mylan (MYL +1.3%) is trying to extricate itself from a controversy over its aggressive price hikes of EpiPen. Investors perceive this bodes well for Adamis.
• Read now What's Going On At Mylan?